Chakkera Harini A, Chertow Glenn M, O'Hare Ann M, Amend William J, Gonwa Thomas A
Division of Transplantation, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
Clin J Am Soc Nephrol. 2009 Jan;4(1):152-9. doi: 10.2215/CJN.02050408. Epub 2008 Oct 15.
Clinical outcomes after kidney transplant have improved considerably in the United States over the past several decades. However, the degree to which this has occurred uniformly across the country is unknown.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Regional variations in graft failure after kidney transplant during three different time periods were examined. These time periods were chosen to coincide with major shifts in immunosuppressant usage: Era 1, cyclosporine usage, 1988 through 1989; Era 2, introduction of tacrolimus and mycophenolate mofetil, 1994 through 1995; and Era 3, widespread use of tacrolimus and mycophenolate mofetil, 1998 through 1999. Patient data were obtained from the United States Renal Data System database. For each period, regional differences in time from transplant to graft failure (organ removal, death, or return to dialysis) were examined. For each region, differences in graft failure over time were examined.
One-year graft survival rates ranged from 76% to 83% between regions in Era 1 (n = 13,669), from 84% to 89% in Era 2 (n = 17,456), and from 87.5% to 92% in Era 3 (n = 20,375). Three-year graft survival ranged from 65% to 75% between regions in Era 1, from 84% to 89% in Era 2, and from 77% to 86% in Era 3. Adjusted models for donor and recipient characteristics showed improvements in graft survival over time in all United Network for Organ Sharing regions with minimal variation across regions.
Regional differences in graft survival after kidney transplant are minimal, particularly when compared with the dramatic improvements in graft survival that have occurred over time.
在过去几十年中,美国肾移植后的临床结局有了显著改善。然而,全国范围内这种改善的程度是否一致尚不清楚。
设计、地点、参与者与测量方法:研究了三个不同时间段肾移植后移植物失败的区域差异。选择这些时间段是为了与免疫抑制剂使用的重大转变相吻合:第1阶段,1988年至1989年使用环孢素;第2阶段,1994年至1995年引入他克莫司和霉酚酸酯;第3阶段,1998年至1999年广泛使用他克莫司和霉酚酸酯。患者数据来自美国肾脏数据系统数据库。对于每个时间段,研究了从移植到移植物失败(器官切除、死亡或恢复透析)的时间的区域差异。对于每个区域,研究了移植物失败随时间的差异。
在第1阶段(n = 13,669),各区域之间的1年移植物存活率在76%至83%之间;在第2阶段(n = 17,456),为84%至89%;在第3阶段(n = 20,375),为87.5%至92%。第1阶段各区域之间的3年移植物存活率在65%至75%之间,第2阶段为84%至89%,第3阶段为77%至86%。对供体和受体特征的校正模型显示,随着时间的推移,器官共享联合网络所有区域的移植物存活率均有所提高,各区域间差异最小。
肾移植后移植物存活的区域差异很小,特别是与随着时间推移移植物存活的显著改善相比。